Colossal Laboratories & Biosciences Stock for Accredited Investors
Colossal Laboratories & Biosciences is a private biotechnology company focused on de-extinction, genetic engineering, and species restoration. It develops CRISPR-based and reproductive technologies aimed at conserving biodiversity and restoring extinct species for accredited investors. In September 2025, Colossal Laboratories & Biosciences raised $120 million in its Series C at a $10.32 billion post-money valuation, led by U.S. Innovative Technology Fund, Bob Nelsen and Peter Jackson (Bloomberg and TechCrunch).
Access to pre-IPO shares is available to accredited investors through UpMarket.